Sustained Release Injectables to 2026

sustained release injectables   Sustained Release Injectables • August 2019  •  Catalog no. SJB982  •  Price US $3,850

 


Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug’s release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables will increase.

Blue document  Sustained Release Injectables to 2026 Report Brochure (Download PDF)

Bar_Graph  Sustained Release Injectables to 2026 Report Order Form (Download PDF)

 

Sustained Release Injectables – What You Will Learn

• What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them?
• What are the major factors driving sustained release injectable drug demand?
• What sustained release injectable drug candidates are in late-stage clinical development and what is their potential impact?
• How important are drug developer-formulation technologist relationships in the sustained release market segment, and what are the key alliances in the industry?
• What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for sustained release injectable drug products?
• In what therapeutic market segments do sustained release injectables compete? What is their market share today? What will it be in 2026? What is their expected growth rate?
• What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables?

Sustained Release Injectables – Summary of Contents

Executive Summary

Executive Summary
Injectable Drug Market Dynamics
The Trend toward Self-Administration
Injectable Drug Formulation Technology
Innovation in Injectable Device Designs
Therapeutic Demand Drivers
Market Factors
Competitive Landscape
Risk Factors

Sustained Release – Branded Formulation Technologies
Biodegradable Polymers
Branded SR Formulation Technologies
Physical Process Control Methods

Sustained Release Injectables – Development Factors
Formulation Factors
Stability
Lyophilization
Packaging
Administration Factors

SR Injectables – Product Analysis & Market Sector Forecasts
Addiction
Naltrexone
Diabetes
Exenatide
Infectious Disease
Interferon
Hormone Deficiency
Estradiol
Somatropin
Testosterone
Metabolic Diseases
Acromegaly
Lanreotide
Octreotide
Neurology
Aripiprazole
Fluphenazine
Haloperidol
Paliperidone
Olanzapine
Risperidone
Oncology
Leukemia
Vincristine
Lymphoma
Cytarabine
Prostate
Goserelin
Leuprolide
Triptorelin
Pain Management
Bupivacaine
Reproductive Health
Medtroxyprogesterone

Development-stage SR Injectables

Company Profiles

 

Useful Links:

Sustained release Injectables